tert-butyl 4-(3-methoxyquinoxalin-2-yl)piperazine-1-carboxylate | 1065484-41-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(3-methoxyquinoxalin-2-yl)piperazine-1-carboxylate
• CAS: 1065484-41-4
• 化学式: C₁₈H₂₄N₄O₃
• 分子量: 344.414
• InChiKey: LMDJVNQXWRAAES-UHFFFAOYSA-N

物化性质

• 密度：
  1.21

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-methoxyquinoxalin-2-yl)piperazine-1-carboxylate 、 三氟乙酸 以 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 为溶剂， 以88%的产率得到
  参考文献：
  名称：

  [EN] GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS
  [FR] INHIBITEURS DE POMPE D'EFFLUX DE BACTÉRIES À GRAM NÉGATIF

  摘要：

  The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity of antibiotics. Infections by multidrug resistant (MDR) Gram-negative bacteria are a major threat to global healthcare. The inventors have discovered a novel class of Resistance Nodulation cell Division-efflux pump inhibitors. The inventors tested the effects of these inhibitors on growth inhibition of different bacteria as well as their impact on the boosting of antibiotic activity in different bacteria. Particularly, the inventors tested the effects of these inhibitors on E. coli, A. baumannii, K. pneumoniae and P. aeruginosa.

  公开号：

  WO2023002011A1
• 作为产物：
  描述：

  甲醇 、 tertiary-butyl 4-(3-chloro quinoxalin-2-yl) piperazine-1-carboxylate 在 potassium carbonate 作用下， 以74%的产率得到tert-butyl 4-(3-methoxyquinoxalin-2-yl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS
  [FR] INHIBITEURS DE POMPE D'EFFLUX DE BACTÉRIES À GRAM NÉGATIF

  摘要：

  The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity of antibiotics. Infections by multidrug resistant (MDR) Gram-negative bacteria are a major threat to global healthcare. The inventors have discovered a novel class of Resistance Nodulation cell Division-efflux pump inhibitors. The inventors tested the effects of these inhibitors on growth inhibition of different bacteria as well as their impact on the boosting of antibiotic activity in different bacteria. Particularly, the inventors tested the effects of these inhibitors on E. coli, A. baumannii, K. pneumoniae and P. aeruginosa.

  公开号：

  WO2023002011A1